Muscular Disease

4

Review clinical trials related to Muscular Disease. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1044 for the treatment of Duchenne Muscular Dystrophy (DMD) with Gene Mutations Amenable to Exon 44 Skipping

Participants needed: 70
Trial details
Phase: Phase 3Age: 7-16Biological sex: MaleType: InterventionalSponsor: Avidity Biosciences, Inc.Updated: Jul 13, 2026
Eligibility criteria

Ambulatory males with clinical and genetic diagnosis of DMD [+4]

Previous treatment cell or gene therapy. [+4]

Status: Not yet recruiting

Hyperthermia in Patients With Chronic Primary Pain - Effects on Thermoregulation, Somatosensory System and Movement Evoked Pain

This study, in a quasi-experimental matched two-group pre-post design, investigates the effect of serial water-filtered whole-body hyperthermia on circadian core body temperature, the somatosensory system (nociception) and the movement evoked pain in healthy and patients with chronic primary pain (e.g., fibromyalgia). The intervention lasts 3 weeks with two treatment sessions per week.

Participants needed: 60
Trial details
Age: 18-70Biological sex: AllType: InterventionalSponsor: Bern University of Applied SciencesUpdated: Jun 2, 2026Locations: 1
Eligibility criteria

Confirmed diagnosis of widespread pain (ICD-11 MG30.01) [+9]

Participation in other clinical studies [+7]

Status: Not yet recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1044 for the treatment of Duchenne Muscular Dystrophy (DMD) with Gene Mutations Amenable to Exon 44 Skipping

Participants needed: 70
Trial details
Phase: Phase 3Age: 7-16Biological sex: MaleType: InterventionalSponsor: Avidity Biosciences, Inc.Updated: May 14, 2026
Eligibility criteria

Ambulatory males with clinical and genetic diagnosis of DMD [+4]

Previous treatment cell or gene therapy. [+4]

Status: Recruiting

Study of Inherited Neurological Disorders

This study is designed to learn more about the natural history of inherited neurological disorders and the role of heredity in their development. It will examine the genetics, symptoms, disease progression, treatment, and psychological and behavioral impact of diseases in the following categories: hereditary peripheral neuropathies; hereditary myopathies; muscular dystrophies; hereditary motor neuron disorders; mitochondrial myopathies; hereditary neurocognitive disorders; inherited neurological disorders without known diagnosis; and others. Many of these diseases, which affect the brain, spinal cord, muscles, and nerves, are rare and poorly understood. Children and adults of all ages with various inherited neurological disorders may be eligible for this study. Participants will undergo a detailed medical and family history, and a family tree will be drawn. They will also have a physical and neurological examination that may include blood test and urine tests, an EEG (brain wave recordings), psychological tests, and speech and language and rehabilitation evaluations. A blood sample or skin biopsy may be taken for genetic testing. Depending on the individual patient s symptoms, imaging tests such as X-rays, CT or MRI scans and muscle and nerve testing may also be done. Information from this study may provide a better understanding of the genetic underpinnings of these disorders, contributing to improved diagnosis, treatment, and genetic counseling, and perhaps leading to additional studies in these areas.

Participants needed: 3,500
Trial details
Age: 2-120Biological sex: AllType: ObservationalSponsor: National Institute of Neurological Disorders and Stroke (NINDS)Updated: Apr 14, 2026Locations: 2
Eligibility criteria

Participants include those with inherited neurological conditions based on the t... [+3]